Sarepta Therapeutics, Inc. (NASDAQ:SRPT)‘s stock had its “buy” rating restated by equities researchers at SunTrust Banks, Inc. in a research note issued on Thursday. They currently have a $56.00 price target on the biotechnology company’s stock. SunTrust Banks, Inc.’s target price would suggest a potential upside of 23.40% from the company’s previous close.

A number of other research firms have also weighed in on SRPT. Barclays PLC assumed coverage on Sarepta Therapeutics in a research report on Wednesday. They set an “equal weight” rating and a $46.00 price objective on the stock. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $76.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday. Credit Suisse Group upped their price objective on Sarepta Therapeutics from $5.65 to $81.00 and gave the stock an “outperform” rating in a research report on Thursday. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $55.00 price objective (up previously from $50.00) on shares of Sarepta Therapeutics in a research report on Thursday. Finally, William Blair reaffirmed an “outperform” rating on shares of Sarepta Therapeutics in a research report on Thursday. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $62.31.

Shares of Sarepta Therapeutics (SRPT) traded down 2.89% during mid-day trading on Thursday, reaching $45.38. The company’s stock had a trading volume of 3,787,888 shares. Sarepta Therapeutics has a one year low of $25.47 and a one year high of $63.73. The stock’s market cap is $2.92 billion. The stock has a 50 day moving average of $38.96 and a 200-day moving average of $34.02.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.46. The company had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. During the same period in the prior year, the company posted ($1.19) EPS. The firm’s revenue was up 350000.0% compared to the same quarter last year. On average, equities research analysts expect that Sarepta Therapeutics will post ($1.17) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/07/sarepta-therapeutics-inc-srpt-stock-rating-reaffirmed-by-suntrust-banks-inc.html.

In other news, SVP Alexander Cumbo sold 5,918 shares of the stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $242,638.00. Following the completion of the sale, the senior vice president now owns 22,793 shares in the company, valued at $934,513. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Md Kaye sold 10,000 shares of the stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total transaction of $410,000.00. Following the sale, the director now owns 62,471 shares of the company’s stock, valued at approximately $2,561,311. The disclosure for this sale can be found here. Insiders have sold 78,056 shares of company stock valued at $3,224,208 in the last quarter. Insiders own 9.60% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Prentiss Smith & Co. Inc. boosted its stake in shares of Sarepta Therapeutics by 772.2% during the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after buying an additional 3,166 shares during the period. Ameritas Investment Partners Inc. acquired a new stake in shares of Sarepta Therapeutics during the first quarter worth about $127,000. Cubist Systematic Strategies LLC boosted its stake in shares of Sarepta Therapeutics by 116.4% during the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after buying an additional 2,474 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Sarepta Therapeutics by 150.1% during the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after buying an additional 2,800 shares during the period. Finally, Edge Wealth Management LLC acquired a new stake in shares of Sarepta Therapeutics during the second quarter worth about $175,000. Institutional investors and hedge funds own 65.43% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.